1. Visit Alma Beauty
  2. Distributors
  3. Contact
  4. International
  1. Products
  2. Treatments
  3. For Patients
  4. Events
  5. News
  6. Company
  7. Blog
  8. Clinical Resources
Back

07/30/2008

Alma Lasers Announces FDA Clearance of the Pixel® CO2 OMNIFIT Handpiece


Alma Lasers Announces FDA Clearance of the Pixel® CO2 OMNIFIT Handpiece
New high-tech handpiece gives physicians’ practices a face lift

Chicago, IL (July 30, 2008) – Alma Lasers Ltd. (“Alma”), a leader in laser, light, and radiofrequency-based aesthetic devices, announced today the FDA clearance and immediate availability of the Pixel CO2 OMNIFIT handpiece at The American Academy of Dermatology Summer Meeting in Chicago. The Pixel CO2 OMNIFIT is Alma’s newest offering in skin rejuvenation and it is an upgrade to physicians’ existing CO2 skin resurfacing lasers. It is designed to provide patients with impressive results with just a fraction of the downtime compared to current treatments, and for significantly less money than replacing their current laser.

The Pixel CO2 OMNIFIT handpiece fits onto most existing CO2 lasers and is designed to deliver a high degree of efficacy without the side effects or significant downtime associated with traditional CO2 resurfacing. By combining Alma’s proprietary and proven Pixel fractional technology with a standard CO2 resurfacing laser, the new Pixel CO2 OMNIFIT delivers a supremely effective treatment for aged, photo-damaged, and acne-scarred skin with minimal patient redness, irritation or downtime.

“We are extremely pleased to announce the FDA’s clearance of the Pixel CO2 OMNIFIT handpiece for skin resurfacing as it offers patients an effective treatment with minimal downtime compared to existing treatments,” said Howard Kelly, CEO of Alma Lasers. “This latest regulatory milestone allows us to continue to build on the success we have had with meeting physicians’ needs for innovative and patient-focused solutions in the current aesthetic treatment marketplace.”

The Pixel CO2 OMNIFIT handpiece takes ablative patient downtime from 30 days to approximately three, making the procedure as appealing as many non-invasive approaches available to today’s busy patients.

“I have had outstanding results treating my patients with fractionated CO2 skin resurfacing, says Dr. Benjamin J. Raab, Assistant Professor of Clinical Dermatology at Northwestern University Medical School and a Board Certified Dermatologist. “This will soon become the treatment of choice for patients seeking significant cosmetic improvements for aging and photo-damage without complications or prolonged healing time.”



Files for Download